 |
 |
 |
 |
 |
 |
 |
Member Information
Hildegund Ertl, MD
Professor, The Wistar Institute
Office Phone: 215 898-3863
Office Fax: 215 573-3953
Email: ertl@wistar.org
Website(s): http://www.wistar.org/ertl/
Education: MD 1977, Georg August University , Goettingen , Germany
Keywords: HIV Vaccines
Research and/or Clinical Interests:
Develop simian adenoviral recombinant vaccines to HIV-1
Summary:
One of the goals of the Ertl laboratory is to establish in rodents the immunogenicity of novel vaccine carriers based on E1-deleted chimpanzee serotypes of adenovirus.
The laboratory characterizes aspects of the immune responses to the transgene products expressed by the novel vaccines that are related to the carrier rather than the inserted HIV-1 sequences. The following studies are being conducted: [a] Test the magnitude of the immune responses in relation to vaccine dose and route of application; [b] Define the type of the induced immune response (Th1/Th2); [c] Determine the anatomic distribution of effector or memory T cells (central versus mucosal) depending on the route of immunization; [d] Test for potential interference by pre-existing immunity to unrelated common human serotypes of adenovirus; [e] Determine the effect of heterologous prime boost regimens; [f] Determine the longevity of the response [g] Characterize the initial vaccine-induced inflammatory response. B cell responses are analyzed with a construct expressing gp140 of a reference strain of clade B.
Representative Publications:
Farina, S.F., Gao, G., Xiang, Z.Q., Rux, J.J., Burnett, R.M., Alvira, M.R., Marsh, J., Ertl, H.C.J., Wilson, J.M. Replication-defective vector based on a chimpanzee adenovirus. Journal of Virology 75: 11603-13, 2001.
Xiang, Z.Q., Gao, G., Reyes-Sandoval, A., Cohen, C.J., Li, Y., Bergelson, J.M., Wilson, J.M., Ertl, H.C.J. Novel, adenoviral vaccine carrier based on the chimpanzee serotype 68 for induction of antibodies to a transgene product. Journal of Virology 76: 2667-2675, 2002.
Blaszczyk-Thurin, M., O, I. , Ertl, H.C.J. An experimental vaccine expressing wild-type p53 for prevention of cancer. Scand. Journal of Immunology 56: 361-375, 2002.
O, I. , Ku, G., Ertl, H.C.J. Blaszczyk-Thurin, M. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Research 22: 613-621 , 2002.
Ertl, H.C.J. Viral Immunology. In Fundamental Immunology, W.E. Paul, ed. Lippincott, Williams and Wilkins, Philadelphia , PA , 2002.
Vinner, L., Wee, E.G.T., Patel, S., Corbet, S., Gao, G.P., Therrien, D., Nielsen, C., Wilson, J.M., Ertl, H.C.J., Hanke, T., Fomsgaard, A. Immunogenicity in Mamu-A01 Rhesus Macques of a CR5-Tropic HIV-1 envelop from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus-5 boost. Statens Serum Institut web communiqué , 2002.
Deng, H., Kowalczyk, D.W., O, I. , Blaszczyk-Thurin, M., Xiang, Z.Q., Giles-Davis, W., Ertl, H.C.J. A modified DNA vaccine to p53 induces protective immunity to challenge with a chemically induced sarcoma cell line. Cellular Immunology 215: 20-31, 2002.
DNA Vaccines. Ertl, H.C.J., ed. Landes Biosciece, Houston, TX & Kluwer Academic, Plenum Publishers, New York, NY, 2003.
Fitzgerald, J., Gao, G.P., Reyes-Sandoval, A., Pavlakis, G.N., Xiang, Z.Q., Wlazlo, A.P., Giles-Davis, W., Wilson , J., and Ertl, H.C.J. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. Journal of Immunology 170: 1416-1422, 2003.
Z. Q. Xiang, G. P. Gao, Y. Li, J. M. Wilson, H. CJ. Ertl. T Helper cell-independent antibody responses to the transgene product of the E1-deleted adenoviral vaccine require NK1.1 T cells. Virology, 305: 397-405, 2003.
Vinner, L., Wee, E.G., Patel, S., Corbet, S., Gao, G.P., Nielsen, C., Wilson, J.M., Ertl, H.C.J., Hanke, T., Fomsgaard , A. Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost . Journal of General Virology 84: 203-213 , 2003.
Ertl, H.C.J. Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion. Current Opinion in Molecular Therapy 4:601-605, 2003.
